Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Core Points - Adial Pharmaceuticals has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until March 2, 2026 to meet this requirement [1][2] - The company must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the extension period [2] - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 showing promising results in a Phase 3 clinical trial for Alcohol Use Disorder [3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing treatments for addictions and related disorders [3] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder and potentially other addictive disorders [3]